536565
NOVELIX
Start SIP
Invest Now
Start SIP in NOVELIX
Performance
- Low
- ₹59
- High
- ₹63
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹63
- Previous Close₹63
- Volume6,653
- 50 DMA₹58.88
- 100 DMA₹54.71
- 200 DMA₹46.11
Investment Returns
- Over 1 Month + 13.06%
- Over 3 Month + 1.29%
- Over 6 Month + 54.6%
- Over 1 Year + 142.17%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 59.2
- PEG Ratio
- 0.1
- Market Cap Cr
- 108
- P/B Ratio
- 3.8
- Average True Range
- 3.71
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.14
- RSI
- 53.3
- MFI
- 47.88
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹61.39
-1.61
(-2.56%)
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹60.88
- 50 Day
- ₹58.88
- 100 Day
- ₹54.71
- 200 Day
- ₹46.11
Resistance and Support
61.15
- R3 67.38
- R2 65.22
- R1 63.31
- S1 59.24
- S2 57.08
- S3 55.17
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- NOVELIX
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹61 As on 18 February, 2026 | 04:01
The Market Cap of Novelix Pharmaceuticals is ₹108.1 Cr As on 18 February, 2026 | 04:01
The P/E ratio of Novelix Pharmaceuticals is 59.2 As on 18 February, 2026 | 04:01
The PB ratio of Novelix Pharmaceuticals is 3.8 As on 18 February, 2026 | 04:01
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.